Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00078039
Recruitment Status : Completed
First Posted : March 12, 2004
Last Update Posted : June 8, 2011
Sponsor:
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Tracking Information
First Submitted Date  ICMJE February 17, 2004
First Posted Date  ICMJE March 12, 2004
Last Update Posted Date June 8, 2011
Study Start Date  ICMJE March 2004
Primary Completion Date Not Provided
Current Primary Outcome Measures  ICMJE
 (submitted: January 21, 2008)
Change from baseline in total PANSS score to the end of the double-blind phase.
Original Primary Outcome Measures  ICMJE
 (submitted: June 23, 2005)
Change in the PANSS total score
Change History Complete list of historical versions of study NCT00078039 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: January 21, 2008)
Assessment of global improvement in severity of illness; Evaluations of the benefits to quality of life; Assessment of the benefits to personal and social functioning. Incidence of adverse events throughout study.
Original Secondary Outcome Measures  ICMJE
 (submitted: June 23, 2005)
  • Assessment of global improvement in severity of illness
  • Evaluations of the benefits to QoL
  • Assessment of the benefits to personal and social functioning
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
Official Title  ICMJE Randomized, Double-blind, Placebo- and Active-controlled Parallel Group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (6, 9, and 12 mg/Day) and Olanzapine (10 mg/Day) With Open-label Extension in Treatment of Schizophrenia
Brief Summary The primary objective of the double blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (6, 9, and 12 mg/day) compared with placebo in adult patients with schizophrenia.
Detailed Description

Paliperidone is being developed as a new therapeutic agent for the treatment of schizophrenia. The ER formulation of paliperidone was developed to deliver paliperidone at a relatively constant rate over a 24-hour period to improve the tolerability profile and decrease the potential for orthostatic hypotension. This study is designed to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (6, 9, and 12 mg/day) compared with placebo in patients with schizophrenia. This trial is a multicenter, double-blind (neither the patient nor the physician will know if placebo or drug is being given and at what dose), randomized (patients will be assigned to different treatment groups based solely on chance), placebo- and active-controlled, parallel-group, dose-response study. The study includes a screening period of up to 5 days, followed by double-blind treatment phase of 6 weeks. Following the double-blind treatment phase, eligible patients (those who have completed the 6-week double-blind phase or who discontinue due to lack of efficacy after a minimum of 21 days) may enter a 52-week open-label extension phase with paliperidone ER monotherapy. Patients will be randomly assigned to 1 of 5 treatments (paliperidone ER 6, 9, or 12 mg, olanzapine 10 mg, or placebo) and will take oral dosages of assigned treatment once daily during the 6-week double-blind period. At the time patients enter the double-blind period, they must be inpatients, and must remain in the hospital for a minimum of 14 full days. While patients are hospitalized, efficacy will be assessed twice during the first week and at the end of the second week. After patients are discharged from the hospital, they will return to have efficacy and safety assessments performed on a weekly basis through the end of the 6-week double-blind period. The efficacy response will be measured by the change in the PANSS total score from start of treatment to the end of the double-blind phase. Safety will be monitored throughout the study and includes assessments of the incidence of adverse events; measurement of extrapyramidal symptoms using 3 rating scales (Abnormal Involuntary Movement Scale [AIMS], Barnes Akathisia Rating Scale [BARS], Simpson-Angus Rating Scale [SAS]); measurement of vital signs (lying down and standing blood pressure, pulse, temperature); electrocardiograms; and clinical laboratory tests. Double-blind: 6-, 9-, or 12-mg fixed dose of paliperidone ER, olanzapine 10 mg or placebo taken orally once daily for 6 weeks.

Open-label extension: start on paliperidone ER 9 mg taken orally once a day; maintained on a flexible oral dosage of paliperidone ER (3, 6, 9, or 12 mg/day) for 52 weeks.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Schizophrenia
Intervention  ICMJE Drug: Paliperidone ER
Study Arms  ICMJE Not Provided
Publications * Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008 May;69(5):817-29.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 1, 2010)
630
Original Enrollment  ICMJE
 (submitted: June 23, 2005)
595
Actual Study Completion Date  ICMJE January 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Double-blind phase: DSM-IV diagnosis of schizophrenia at least 1 year prior to screening
  • experiencing an acute episode, with a total PANSS score at screening between 70 and 120
  • agree to voluntary hospitalization for a minimum of 14 days
  • willing and able to fill out self-administered questionnaires
  • able to be compliant with self-administration of medication, or have consistent help/support available.

Open-label extension phase: completed the 6 weeks of double-blind treatment or completed at least 21 days of treatment and discontinued due to lack of efficacy

  • patient and investigator agree that open-label treatment is in the best interest of the patient.

Exclusion Criteria:

  • Double-blind phase: DSM-IV axis I diagnosis other than schizophrenia
  • DSM-IV diagnosis of substance dependence within 6 months prior to screening evaluation (nicotine and caffeine dependence are not exclusionary)
  • history of tardive dyskinesia or neuroleptic malignant syndrome (NMS)
  • history of any severe preexisting gastrointestinal narrowing (pathologic or iatrogenic)
  • previous history of lack of response (2 adequate trials) to any antipsychotic
  • significant risk of suicidal or violent behavior. Open-label phase: At significant risk for suicidal or violent behavior
  • received an injection of a depot antipsychotic since entry into the preceding double-blind phase.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries Bulgaria,   Croatia,   Estonia,   France,   Greece,   India,   Netherlands,   Poland,   Russian Federation,   Slovakia,   Spain
 
Administrative Information
NCT Number  ICMJE NCT00078039
Other Study ID Numbers  ICMJE CR003379
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
PRS Account Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Verification Date April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP